The in-license of the NuroPro Blood Test for Parkinson’s disease expands our product offering as we strive to become the leader in the evaluation and treatment of Parkinson’s disease
Scottsdale, AZ (PRWEB) January 29, 2012
QualityStocks would like to highlight Amarantus Biosciences, Inc., a publicly traded company. Amarantus BioSciences is a California-based development-stage biotechnology company founded in January 2008. The company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases.
In the company’s news last week,
Amarantus Biosciences, Inc. announced it has signed an exclusive worldwide license agreement with Power3 Medical Products, Inc. for the NuroPro® Blood Test as it relates to Parkinson’s disease diagnosis.
Per the initial one-year agreement, Amarantus has an exclusive license to develop, manufacture, have manufactured, use, market, sell and import medical devices and methods under the Power3 Parkinson’s Disease Intellectual Property (IP). Amarantus now also has an exclusive, royalty-free, fully paid-up worldwide license to Power3 know-how, patents and patent applications which relate to medical devices and methods for the treatment of neurodegenerative disease as it relates to Parkinson’s disease.
The NuroPro Blood Test is a diagnostic platform designed to assist physicians to more accurately diagnose disease and monitor progression, and has the ability to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. Amarantus’ license is focused on the further development to specifically target the early diagnosis and ongoing monitoring of Parkinson’s disease.
The licensing agreement enhances Amarantus’ market position and advances its MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) therapeutic, for which it currently was awarded the composition of matter patent by the U.S. Patent & Trademark Office.
“The in-license of the NuroPro Blood Test for Parkinson’s disease expands our product offering as we strive to become the leader in the evaluation and treatment of Parkinson’s disease,” Gerald Commissioning, president and CEO of Amarantus stated in the press release. “Now that we will be able to tailor our therapeutic development pathway towards a companion diagnostic product that we control, Amarantus is positioned to build a strategic advantage over competitors as the execution of our clinical and regulatory strategy continues to advance MANF as a disease-modifying treatment for Parkinson’s disease.”
The NuroPro Blood Test has undergone proof-of-concept and phase 1 clinical validation studies for Parkinson’s disease application, and Amarantus said it plans to initiate a phase 2 clinical validation study in the first half of 2012.
Per the agreement, Amarantus paid a $25,000 exclusivity fee in common stock on November 11, 2011, and will issue to Power3 $475,000 worth of common stock. Amarantus has an option to purchase all of the Parkinson’s Disease IP owned by Power3 for $500,000 worth of common stock and maintains a Right of First Refusal to acquire the balance of the NuroPro platform for Alzheimer’s, ALS and all other neurodegenerative diseases.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.